GlassScriptPhysician profile
Peter Dg Chang Sing
NPI 1386678902
$31,473.64
in general payments reported to CMS, 2019-2025
23 companies · $1,193 in 2025
The $1,193 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,837 · 2020: $4,128 · 2021: $2,862 · 2022: $3,556 · 2023: $10K · 2024: $2,708 · 2025: $1,193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,519 · Food and Beverage: $4,806 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,754 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,519.06 |
| Food and Beverage | $4,805.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,754.00 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $14,165.50 | 2021-2025 | Pulseselect, Micra, Flexcath Advance |
| Medtronic Vascular, INC. | $7,894.76 | 2019-2020 | |
| Boston Scientific Corporation | $4,995.75 | 2019-2025 | Watchman Flx, Watchman, Rhythmia Mapping System |
| Abbott Laboratories | $787.58 | 2019-2025 | 2nd Gen Centrimag Primary Console, Cardiomems, Triclip |
| Sanofi-Aventis U.S. LLC | $694.59 | 2019-2023 | |
| Biosense Webster, INC. | $664.99 | 2019-2025 | Carto 3 |
| Merck Sharp & Dohme LLC | $426.29 | 2021-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $289.71 | 2022-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.54 | 2019-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $252.23 | 2022-2024 | Lifevest |
| Edwards Lifesciences Corporation | $163.85 | 2023 | |
| Atricure, INC. | $144.76 | 2025 | Synergy Ablation System, Atriclip Laa Exclusion System |
| Angiodynamics, INC. | $142.21 | 2019 | |
| Abiomed | $135.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $122.47 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $78.51 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $58.66 | 2023 | Farxiga |
| Bardy Diagnostics, INC. | $49.95 | 2020-2022 | |
| Biotronik INC. | $40.91 | 2019 | |
| Kestra Medical Technology Services, INC. | $39.69 | 2023-2024 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $26.82 | 2023 | Amvuttra |
| Irhythm Technologies, INC. | $22.81 | 2024 | Zio Xt Patch, Zio Monitor |
| Novartis Pharmaceuticals Corporation | $18.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Chang Sing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.